Arvinas Holding Company (ARVN)
NASDAQ:ARVN
Want to see ARVN full AI Analyst Report?
Top Page
Arvinas Holding Company
(NASDAQ:ARVN)
Select Model
Select Model
Rating:50Neutral
Price Target:
$8.50
▼(-22.73% Downside)
Action:Reiterated
Date:06/03/26
The score is held back primarily by weak financial performance (large losses, sharply lower revenue, and sustained cash burn) and bearish technical trends (below major moving averages with negative MACD). These are partly offset by a constructive earnings-call outlook featuring platform validation via VEPPANU’s FDA approval, cost reductions, and a multi-year cash runway.
Positive Factors
Platform validation (VEPPANU FDA approval)
The FDA approval of VEPPANU materially validates Arvinas’s PROTAC platform, reducing modality risk across the pipeline. This validation strengthens the company’s negotiating position with partners, supports out‑licensing economics, and increases the credibility of follow‑on programs over the coming months.
Negative Factors
Sharp year‑over‑year revenue decline
A collapse in reported revenue driven by collaborative accounting changes and lower vepdegestrant recognition materially reduces near‑term recurring inflows. This weakens visibility into sustained cash generation and increases reliance on milestone and licensing receipts to fund operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform validation (VEPPANU FDA approval)
The FDA approval of VEPPANU materially validates Arvinas’s PROTAC platform, reducing modality risk across the pipeline. This validation strengthens the company’s negotiating position with partners, supports out‑licensing economics, and increases the credibility of follow‑on programs over the coming months.
Read all positive factors
Arvinas Holding Company (ARVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$496.81M
Dividend YieldN/A
Average Volume (3M)898.13K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth-79.06%
EPS Growth-397.92%
CountryUS
Employees430
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.26
Shares Outstanding64,521,194
10 Day Avg. Volume783,260
30 Day Avg. Volume898,130
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit5.75
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$14.69Price Target Upside33.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$122.42M
Arvinas Holding Company Business Overview & Revenue Model
Company Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting ...
How the Company Makes Money
Arvinas primarily makes money through collaboration-based revenue and, potentially in the future, product commercialization if its drug candidates receive regulatory approval. Its key revenue streams include: (1) Collaboration and license revenue:...
Arvinas Holding Company Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call presented several major positive developments — notably the landmark FDA approval of VEPPANU (first heterobifunctional PROTAC approval), a global out-license to Rigel, robust early clinical and compelling preclinical data across multiple programs (ARV-102, ARV-806, ARV-393, ARV-6723, pan-KRAS), a healthy cash runway into H2 2028, and significant non-GAAP expense reductions improving financial flexibility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by collaborative accounting changes), a quarter-over-quarter cash decline, an FDA-requested hold on the U.S. ARV-102 Phase 1b pending chronic NHP tox data (delaying U.S. patient dosing), and competitive/safety uncertainties in the KRAS landscape. Overall, the highlights — including the validation of the platform, key partnerships, and multiple programs advancing — materially outweigh the lowlights, supporting a positive outlook for the company.Positive Updates
First-in-Class FDA Approval of VEPPANU (vepdegestrant)
FDA approved VEPPANU for ESR1-mutant, ER+/HER2- advanced breast cancer — the first-ever heterobifunctional PROTAC degrader approval. Arvinas and Pfizer entered a global licensing agreement with Rigel for commercialization, development and manufacturing; Arvinas/Pfizer to split economics 50/50 for the out-license. Approval validates platform and de-risks modality.
Negative Updates
Sharp Year-over-Year Revenue Decline
Q1 2026 revenue was $15.6 million vs $188.8 million in Q1 2025 — a decrease of $173.2 million (≈91.7% decline), driven by lower revenue recognized from the vepdegestrant collaborative agreement due to changes in estimated remaining program costs.
Read all updates
Q1-2026 Updates
Positive
Negative
First-in-Class FDA Approval of VEPPANU (vepdegestrant)
FDA approved VEPPANU for ESR1-mutant, ER+/HER2- advanced breast cancer — the first-ever heterobifunctional PROTAC degrader approval. Arvinas and Pfizer entered a global licensing agreement with Rigel for commercialization, development and manufacturing; Arvinas/Pfizer to split economics 50/50 for the out-license. Approval validates platform and de-risks modality.
Read all positive updates
Company Guidance
Arvinas reiterated clear near‑term operational and financial guidance: it ended Q1 with $614.9M in cash, cash equivalents and marketable securities (down from $685.4M at year‑end 2025) and expects that cash to fund operations into the second half of 2028 while supporting four ongoing Phase 1 programs; Q1 revenue was $15.6M (vs. $188.8M year‑ago) as vepdegestrant revenue declined, G&A was $19.1M (vs. $26.6M), R&D was $60.3M (vs. $90.8M), non‑GAAP R&D fell ~$25M (‑32%), non‑GAAP G&A fell $10.1M (‑44%) and total non‑GAAP expenses were $67.3M (down $35.1M), reflecting cost reductions that largely finish mid‑2026; program milestones include ARV‑102 U.S. Phase 1b expected to start by end‑2026 pending mid‑2026 chronic NHP tox data (no change to planned global Phase 2 start), ARV‑806 and ARV‑393 clinical updates later in 2026, ARV‑6723 entering the clinic later this year, and anticipated cash inflows from a VEPPANU approval milestone plus upfront/near‑term Rigel milestones.Arvinas Holding Company Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 89.40M | 262.60M | 263.40M | 78.50M | 131.40M | 53.60M |
| Gross Profit | 87.10M | 257.40M | 263.40M | 78.50M | 131.40M | 53.60M |
| EBITDA | -231.70M | -75.30M | -243.60M | -394.80M | -255.00M | -182.40M |
| Net Income | -221.30M | -80.80M | -198.90M | -367.30M | -282.50M | -191.00M |
Balance Sheet | ||||||
| Total Assets | 647.50M | 717.90M | 1.09B | 1.30B | 1.27B | 1.58B |
| Cash, Cash Equivalents and Short-Term Investments | 614.90M | 685.40M | 1.04B | 1.26B | 1.21B | 1.50B |
| Total Debt | 8.60M | 8.90M | 9.70M | 3.20M | 5.50M | 5.00M |
| Total Liabilities | 260.70M | 284.10M | 529.70M | 644.60M | 703.90M | 799.90M |
| Stockholders Equity | 386.80M | 433.80M | 561.70M | 660.00M | 564.90M | 781.70M |
Cash Flow | ||||||
| Free Cash Flow | -256.90M | -275.70M | -261.10M | -350.70M | -280.30M | 554.70M |
| Operating Cash Flow | -254.10M | -273.80M | -259.30M | -347.80M | -273.50M | 559.40M |
| Investing Cash Flow | 351.80M | 407.60M | 34.70M | 203.50M | 242.80M | -1.31B |
| Financing Cash Flow | -91.40M | -91.40M | 7.90M | 374.70M | 4.70M | 278.60M |
Arvinas Holding Company Technical Analysis
Negative
11.00
Price Trends
10.01
Negative
11.32
Negative
10.67
Negative
Market Momentum
-0.61
Positive
25.79
Positive
6.48
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Negative. The current price of 11 is above the 20-day moving average (MA) of 9.01, above the 50-day MA of 10.01, and above the 200-day MA of 10.67, indicating a bearish trend. The MACD of -0.61 indicates Positive momentum. The RSI at 25.79 is Positive, neither overbought nor oversold. The STOCH value of 6.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARVN.
Arvinas Holding Company Risk Analysis
Arvinas Holding Company disclosed 70 risk factors in its most recent earnings report. Arvinas Holding Company reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Arvinas Holding Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $1.49B | -55.34 | 442.91% | ― | 107.73% | 82.33% | |
60 Neutral | $1.31B | -7.88 | -35.89% | ― | ― | -63.41% | |
56 Neutral | $869.60M | -6.46 | 474.91% | ― | 131.13% | 35.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $496.81M | -2.24 | -44.39% | ― | -79.06% | -397.92% | |
46 Neutral | $918.02M | -5.93 | -45.95% | ― | ― | -3.83% | |
45 Neutral | $378.18M | -5.82 | -39.75% | ― | -100.00% | -2.72% |
* Healthcare Sector Average
ARVN
Arvinas Holding Company
7.74
0.82
11.85%
ANAB
AnaptysBio
51.67
37.58
266.69%
MGTX
Meiragtx Holdings
9.57
4.09
74.64%
CMPX
Compass Therapeutics
2.13
-0.23
-9.75%
OLMA
Olema Pharmaceuticals
10.68
6.47
153.68%
BCAX
Bicara Therapeutics Inc.
20.41
9.38
85.04%
Arvinas Holding Company Corporate Events
Business Operations and StrategyFinancial Disclosures
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development
Positive
Jun 2, 2026
Arvinas, Inc. has announced a strategic re-prioritization of its drug development portfolio following an internal pipeline review, signaling a shift in how it allocates resources across its clinical programs. As part of this effort, the company co...
Business Operations and StrategyProduct-Related Announcements
Arvinas Grants Rigel Global Rights to VEPPANU Therapy
Positive
May 12, 2026
On May 11, 2026, Arvinas and its subsidiaries, together with Pfizer, entered a license agreement granting Rigel Pharmaceuticals exclusive global rights to develop, manufacture and commercialize VEPPANU, an FDA-approved oral PROTAC estrogen recepto...
Business Operations and StrategyProduct-Related Announcements
Arvinas Gains First FDA Approval for Breast Cancer Drug
Positive
May 1, 2026
On May 1, 2026, Arvinas and partner Pfizer announced that the U.S. Food and Drug Administration approved VEPPANU (vepdegestrant) for adults with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progres...
Business Operations and StrategyProduct-Related Announcements
Arvinas Reports Positive Phase 1 Data for ARV-102
Positive
Mar 18, 2026
Arvinas, Inc., a clinical-stage biotech focused on PROTAC-based targeted protein degradation, reported positive Phase 1 data on March 18, 2026, for ARV-102, an oral LRRK2 degrader designed to cross the blood-brain barrier in Parkinson’s dise...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.